Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 28;12:888570. doi: 10.3389/fonc.2022.888570

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zhong, Yao, Liu, Zhang, Zhang, Zhang, Lin, Li, Li, Jiang, Cheng, Xu, Wen, Yang, Zhang, Cheng, Huang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The relationship between clinicopathological factors, tumor somatic mutations, immunotherapy and FSscore. (A–D) Correlation analysis between clinicopathological factors and FSscore in the TCGA group, Fisher’s exact test, *P < 0.05. (E, F) The characteristics of tumor somatic mutations in the high and low FS score groups of the TCGA group, WBC: white blood cell, PB: peripheral blood, BM: Bone marrow, IDH: isocitrate dehydrogenase, NPMc: nucleophosmin. (G) Correlation analysis between TMB and FSscore in the TCGA group. (H, I) Differences in survival of patients and the proportion of patients in high and low FSscore groups of immune checkpoint inhibitor treatment cohorts (H: IMvigor210, I: GSE78220), log rank test. (J) Differences in TIDE scores of the high and low FS score groups in the TCGA group. (K) Correlation analysis between TIDE score and FSscore in the TCGA group. (L) The difference in FSscore between drug-resistant and nonresistant patients. ***P < 0.001.